Key Points
- CFO Stephen Carey sold 2,850 ANI Pharmaceuticals shares at an average price of $73, generating $208,050. The transaction, conducted under a pre-arranged Rule 10b5-1 plan, reduced his holdings by 1.66% to 168,993 shares.
- ANI Pharmaceuticals recently exceeded quarterly expectations, reporting $2.21 in earnings per share versus the $2.04 consensus and revenue of $266.04 million, up 25.8% year over year.
- Analyst sentiment is mixed, with the stock carrying an average “Hold” rating and a $98 price target. Institutional investors own approximately 76.05% of the company.
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) CFO Stephen Carey sold 2,850 shares of the firm's stock in a transaction on Tuesday, September 29th. The stock was sold at an average price of $73.00, for a total value of $208,050.00. Following the completion of the transaction, the chief financial officer owned 168,993 shares of the company's stock, valued at $12,336,489. This trade represents a 1.66% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
ANI Pharmaceuticals Stock Performance
Shares of ANIP opened at $72.72 on Thursday. The company has a debt-to-equity ratio of 0.99, a quick ratio of 2.41 and a current ratio of 2.91. The stock has a 50-day moving average of $75.41 and a two-hundred day moving average of $78.11. The stock has a market cap of $1.67 billion, a P/E ratio of 15.67, a P/E/G ratio of 2.34 and a beta of 0.45. ANI Pharmaceuticals, Inc. has a one year low of $69.58 and a one year high of $97.00.
ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last announced its quarterly earnings data on Friday, August 7th. The specialty pharmaceutical company reported $2.21 earnings per share for the quarter, beating analysts' consensus estimates of $2.04 by $0.17. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%.The business had revenue of $266.04 million for the quarter, compared to analyst estimates of $260.13 million. During the same period in the prior year, the company earned $1.80 earnings per share. The company's revenue was up 25.8% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, research analysts predict that ANI Pharmaceuticals, Inc. will post 7.76 EPS for the current year.
Wall Street Analyst Weigh In
A number of research firms have issued reports on ANIP. Canaccord Genuity Group reduced their price target on shares of ANI Pharmaceuticals from $91.00 to $90.00 and set a "hold" rating for the company in a research report on Monday, August 10th. Wall Street Zen downgraded shares of ANI Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Saturday, August 8th. Leerink Partners started coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, September 9th. They issued an "outperform" rating and a $104.00 price objective on the stock. Weiss Ratings cut shares of ANI Pharmaceuticals from a "buy (b-)" rating to a "hold (c+)" rating in a report on Tuesday, August 11th. Finally, Guggenheim decreased their target price on shares of ANI Pharmaceuticals from $124.00 to $119.00 and set a "buy" rating for the company in a research report on Monday, August 10th. Three investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Hold" and an average price target of $98.00.
Read Our Latest Research Report on ANI Pharmaceuticals
Institutional Trading of ANI Pharmaceuticals
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Arrowstreet Capital Limited Partnership raised its position in ANI Pharmaceuticals by 19.3% during the first quarter. Arrowstreet Capital Limited Partnership now owns 564,360 shares of the specialty pharmaceutical company's stock valued at $43,399,000 after acquiring an additional 91,153 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in ANI Pharmaceuticals by 8.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 531,190 shares of the specialty pharmaceutical company's stock worth $40,843,000 after purchasing an additional 43,523 shares in the last quarter. Ranger Investment Management L.P. acquired a new stake in shares of ANI Pharmaceuticals during the 2nd quarter worth approximately $28,406,000. Deutsche Bank AG acquired a new stake in shares of ANI Pharmaceuticals during the 2nd quarter worth approximately $26,775,000. Finally, William Blair Investment Management LLC purchased a new position in shares of ANI Pharmaceuticals during the 2nd quarter valued at approximately $21,372,000. 76.05% of the stock is owned by institutional investors and hedge funds.
About ANI Pharmaceuticals
(
Get Free Report)
ANI Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. The company focuses on products with complex formulations, manufacturing requirements or specialized commercial opportunities, and serves a range of therapeutic areas.
ANI's portfolio includes Cortrophin-Zinc, a repository corticotropin injection used for certain autoimmune and inflammatory conditions, along with a selection of branded and generic medicines.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
